Clinical and immunologic studies of ragweed immunotherapy

Melam, Howard; Pruzansky, Jacob J.; Patterson, Roy; Singer, Steven M.

doi:10.1016/s0091-6749(71)80004-0

Cited by 16 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of patients with decreasing IgE antibody titres during therapy varies from about 50% to almost 100% (Sherman, Stull & Cooke, 1940;Connell & Sherman, 1969;Lichtenstein et al, 1973). The concentration of 'blocking' (IgG) antibody titres remains high or decreases with time (Sherman et al, 1940;Sadan et al, 1969;Melam et al, 1971). The discrepancies between the reported results may reflect differences in the composition of the patient materials and in the schedules used for immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Allergen‐specific IgE and IgG antibodies in pollen‐allergic children given immunotherapy for 2‐6 years

Foucard

Johansson

1978

Clin Experimental Allergy

View full text Add to dashboard Cite

Summary Ninety‐five children with pollen hay fever were treated for 46 months (16‐74 months) with extracts of birch pollen (seventy‐two children) and/or grass pollen (fifty‐nine children). During the first 2 months of this immunotherapy the serum concentration of allergen‐specific IgE antibodies doubled or tripled, but the concentration of IgG‘blocking’antibodies increased even more. With time the IgE antibody activity decreased in 80% of the children, but only in slightly more than 50% did it fall to below the initial level, and the mean concentration at the end of the study was 2‐3 times the initial value. The IgG antibody activity remained high in about 50% of the children and showed a tendency to decrease in the other children, in spite of monthly allergen injections. Eighty‐three out of the ninety‐five children reported a moderate to marked improvement. At the end of the study the eighteen almost symptom‐free children had a higher IgG/IgE antibody ratio than the twelve children who had not improved, but this difference was not significant. After treatment, thirteen children tolerated ten to 10,000 times more allergen than before by naso‐conjunctival challenge tests. Ten of the children reacted to the same allergen dilution as before and two reacted to a ten times weaker extract. Clinical improvement was accompanied by increased tolerance in most patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Allergen‐specific IgE and IgG antibodies in pollen‐allergic children given immunotherapy for 2‐6 years

Foucard

Johansson

1978

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…Allergen complexes, allei-gen-IgE could induce a tolerance of the cells producing IgE (23). The apparent suppression could be the result oi the diminution of immunocompetent cells (17) capable of answering the antigenic stimulus.…”

Section: Imentioning

confidence: 99%

Evolution of Reaginic Antibodies in Specific Hyposensitization

Anfosso-Capra

Vervloët

Autran

et al. 1974

Allergy

View full text Add to dashboard Cite

“…The antibodies would pre sumably neutralise allergens and prevent them from binding to cell-bound reaginic antibody in the underlying mucosa [Giessen et al, 1976;Sobotka et al, 1976;Deuschl et al, 1977;Schumacher and Jeffery, 19791. A number of investigators favour the hy pothesis that the increased levels of IgG an tibodies are responsible for desensitisation [Lichtenstein et al, 1968;Melam et al, 1971;Sobotka et al, 1976;Skov and Norn, 1977;Zeiss et al, 1977], although it is pos sible that locally produced IgA which is pres ent in the upper respiratory tract at higher relative concentrations than IgG is also im portant [Deuschl et al, 1977]. However, the effect of IgA antibodies on various hyper sensitivity reactions does not appear to have been evaluated.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Cutaneous Anaphylaxis and Arthus Reactions in the Mouse by Antigen-Specific IgA

Russell-Jones¹,

Ey²,

Reynolds³

1981

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The nitrophenyl-specific IgA myeloma protein secreted by the MOPC-315 mouse plasmacytoma was examined for its capacity to inhibit antibody-mediated hyper-sensitivity reactions in the mouse. Specific inhibition of both cutaneous anaphylactic and complement-dependent (Arthus) reactions was observed in sensitised mice when the eliciting antigen was mixed with IgA prior to injection or when the mice were injected with plasmacytoma cells and possessed detectable amounts of MOPC-315 IgA in their serum at the time of challenge. The possibility that IgA antibodies have a role in suppressing hypersensitivity reactions at mucosal surfaces is discussed.

show abstract

Clinical and immunologic studies of ragweed immunotherapy

Cited by 16 publications

References 17 publications

Allergen‐specific IgE and IgG antibodies in pollen‐allergic children given immunotherapy for 2‐6 years

Allergen‐specific IgE and IgG antibodies in pollen‐allergic children given immunotherapy for 2‐6 years

Evolution of Reaginic Antibodies in Specific Hyposensitization

Inhibition of Cutaneous Anaphylaxis and Arthus Reactions in the Mouse by Antigen-Specific IgA

Contact Info

Product

Resources

About